Amylyx Pharmaceuticals (AMLX) Depreciation and Depletion (2021 - 2026)

Amylyx Pharmaceuticals' Depreciation and Depletion history runs 6 years deep, the most recent figure standing at $98000.0 for Q1 2026.

• On a quarterly basis, Depreciation and Depletion fell 37.18% year-over-year to $98000.0 in Q1 2026; TTM through Mar 2026 was $467000.0, a 37.32% decrease from a year earlier, with the FY2025 full-year figure at $525000.0, down 41.92% from the prior year.
• Depreciation and Depletion retreated to $98000.0 in Q1 2026 per AMLX's latest filing, from $108000.0 in the prior quarter.
• Across five years, Depreciation and Depletion topped out at $315000.0 in Q1 2024 and bottomed at $35000.0 in Q1 2022.
• The 5-year median for Depreciation and Depletion is $165000.0 (2022), against an average of $182470.6.
• Across the five-year window, Depreciation and Depletion jumped 1550.0% in 2022 and slumped 50.48% in 2025, its largest moves.
• Year by year, Depreciation and Depletion stood at $182000.0 in 2022, then surged by 65.38% to $301000.0 in 2023, then slumped by 46.84% to $160000.0 in 2024, then tumbled by 32.5% to $108000.0 in 2025, then retreated by 9.26% to $98000.0 in 2026.
• Per Business Quant, the three latest AMLX Depreciation and Depletion figures stand at $98000.0 (Q1 2026), $108000.0 (Q4 2025), and $120000.0 (Q3 2025).